



NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) - NOVEL DIAGNOSTIC BIOMARKER OF SEPSIS AND KIDNEY INJURY

Agnieszka PODGÓRSKA^{1,2}, Grzegorz KADE³, Janusz HAŁKA¹

¹ Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Poland

² Nicolaus Copernicus Superior School, Olsztyn, Poland

³ Military Institute of Aviation Medicine, Warsaw, Poland

Source of support: Own sources

Author's address: A. Podgórska, Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Al. Wojska Polskiego 37, 10-228 Olsztyn, e-mail: ag.podgorska95@gmail.com

Abstract: Neutrophil gelatinase-associated lipocalin (NGAL) is a marker of cellular stress, released from various tissues as a result of neutrophil activation. According to literature data, the detection of NGAL is applicable in cardiological conditions, metabolic disorders such as diabetes or dyslipidemia. Moreover, NGAL is recognised as one of the biomarkers of sepsis. Up to 70% of acute kidney injury (AKI) cases may be related to the development of sepsis. Renal tissue injury associated with inflammation, hypoxia or exposure to toxins leads to an increase in plasma NGAL concentration earlier than other commonly used biochemical markers, even as soon as two hours after injury. Studies have demonstrated the utility of NGAL in early diagnosis of AKI, prediction of chronic kidney disease progression, and assessment of graft function following kidney transplantation. Aviators exposed to hypobaric hypoxia, i.e. high altitude hypoxia, are at risk of injury to several organs, including the kidneys. Novel biomarkers can indicate structural kidney damage before renal function deteriorates. The use of NGAL to identify specific sites of renal tissue injury represents an additional area of investigation, as well as a potential target for therapeutic intervention. The aim of the study is to review the current medical knowledge regarding NGAL biomarker, with particular emphasis on its use in the diagnosis of kidney injury and sepsis.

Keywords: NGAL, biomarker, kidney injury, sepsis

Cite this article: Podgórska A, Kade G, Hałka J Neutrophil Gelatinase-Associated Lipocalin (Ngal) - Novel Diagnostic Biomarker of Sepsis and Kidney Injury. Pol J Aviat Med Bioeng Psychol 2023; 29(2): 15-20. DOI: 10.13174/pjambp.25.04.2025.02

Copyright: © Military Institute of Aviation Medicine, 54/56 Krasynskiego St., 01-755 Warsaw, Poland • **License:** CC BY-NC 4.0 • **Indexation:** Ministry of Science and Higher Education (Poland) • **Full-text PDF:** <http://www.pjambp.com>

INTRODUCTION

Neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2 (LCN-2) or siderocalin, described by Kjeldsen et al. in 1993, is a marker of cellular stress, released from various tissues as a result of neutrophil activation [10,19,43]. In addition to neutrophils, other known sources of NGAL are macrophages, dendritic cells, adipocytes, epithelial cells, and tubular cells in the kidney, heart, liver, stomach, lung, colon. NGAL exists in several forms: a 25kDa monomer released by renal tubules, a 45kDa homodimer released by activated neutrophils and 145kDa complex of NGAL and matrix metalloproteinase-9 [19,35].

NGAL is an acute phase protein that plays a role in antibacterial, antiviral and antifungal immune responses [2,11,35]. As a siderophore-binding protein preventing bacterial acquisition of iron, NGAL has a bacteriostatic role, limiting growth and multiplication of pathogens. In addition, NGAL acts as a chemoattractant for neutrophils, affecting neutrophil maturation, adhesion and extravasation, promoting phagocytosis. Furthermore, NGAL is possibly involved in modulating cell-mediated immunity, by participating in activation of T lymphocytes [25,31]. According to Miharada et al. increased secretion of NGAL during infections, particularly in chronic inflammatory diseases, involves apoptosis of hematopoietic progenitors of red blood cells, that contribute to anemia development [29].

The utility of NGAL as a biomarker is related to its biological function. NGAL levels could be measured primarily in plasma and urine, but also it is also detectable in peritoneal effluent, cerebrospinal fluid, saliva, tears, human breast milk, vaginal fluid, bronchoalveolar fluid and amniotic fluid [4,35,45,50].

Elevated level of NGAL can be detected and used as a marker and predictor in a number of cardiovascular conditions such as hypertension, atherosclerosis, acute and chronic heart failure and myocardial infarction. Studies have shown that patients suffering from chronic heart failure and elevated levels of serum NGAL have a higher mortality rate, indicating that NGAL may serve as a potential prognostic marker of survival in this population [5,35]. Similarly, in myocardial infarction increased concentrations of serum NGAL have been associated with worse outcomes [12]. According to Lindberg et al., NGAL is an independent predictor of major adverse cardiovascular events and mortality following ST-elevation myocardial infarction (STEMI) [16].

NGAL concentration may also correlate with metabolic disorders such as diabetes, insulin re-

sistance, obesity and dyslipidemia. The measurement of urinary NGAL may serve as an early marker of diabetic nephropathy [32].

NGAL could affect cell stimulation and differentiation as well as play a role in carcinogenesis of breast, thyroid, prostate, stomach and esophageal cancers [8,9,17,21,37,44]. There potential for research into the use of NGAL as a diagnostic marker and a therapeutic target. Intensive chemotherapy protocols, particularly those involving nephrotoxic agents and systemic complications such as severe infections, highlight the need for markers allowing early detection of organ damage. This would facilitate the timely identification of at-risk patients, the implementation of preventive measures and the initiation of appropriate treatment. Moreover, oncology patients undergoing chemotherapy, struggling with its side effects such as nausea and vomiting, diarrhea, receiving numerous additional drugs such as antibiotics and painkillers, and undergoing imaging tests with intravenous contrast agents are at risk of developing AKI. Shinke et al., found that NGAL may serve as an early biomarker of AKI in patients treated with cisplatin-based chemotherapy protocols [41]. According to Latoch et al., exposure to nephrotoxic chemotherapy such as methotrexate, cyclophosphamide, high doses of glucocorticosteroids and radiotherapy results in elevated NGAL levels, even years after treatment [22].

Sepsis

NGAL is an inherent component of the inflammatory process. Tissue injury associated with infection leads to an increase in plasma NGAL concentration [35]. By participating in the pathogenesis of inflammation, NGAL may serve as a biomarker of sepsis.

Sepsis is a dynamic condition which could rapidly progress to severe sepsis, septic shock and death, if not promptly recognized [13]. Unfortunately, the lack of specific symptoms hinder rapid diagnostics, therefore, sepsis remains a cause of high of morbidity and mortality worldwide. The qSOFA (quick Sequential Organ Failure Assessment Score) and SIRS (Systemic Inflammatory Response Syndrome) criteria used in the diagnosis of sepsis demonstrate sensitivities and specificities of 70% and 73% for qSOFA and 88% and 34% for SIRS, respectively [1]. Similarly, commonly used markers such as C-reactive protein (CRP) and procalcitonin (PCT) also exhibit low sensitivity and specificity [2]. Furthermore, in one-third of the blood cultures tested, no growth of pathogens

responsible for disease development is observed [3]. Rapid and early diagnosis and initiation of appropriate treatment improves outcomes in septic patients. Elevated NGAL levels correlate with other known inflammatory markers such as interleukine-6 (IL-6), interleukine-10 (IL-10), vascular cellular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), tumor necrosis factor alpha (TNF- α), the C-reactive protein and leukocytes account [26]. Plasma NGAL levels appear to have a stronger correlation with absolute neutrophil count than with other inflammatory cytokines, although NGAL can still be detected in patient with neutropenia and systemic inflammation, albeit at lower levels. Nevertheless, urinary NGAL levels may be significantly elevated in patients with AKI and neutropenia [34].

The kinetics of the biomarker responses may affect diagnostic and prognostic accuracy, particularly in rapidly progressing diseases [23]. According to Wang et al., monitoring the activity of TNF- α , NGAL, and IL-6 may contribute significantly to the diagnosis and assessment sepsis severity [46]. The correlation between NGAL and other sepsis markers may also aid in distinguishing patients with severe sepsis from those with more benign clinical course [27]. In a study by Shapiro et al., a biomarker panel comprising NGAL, interleukin-1 receptor antagonist (IL-1Ra) and C-reactive protein was predictive of severe sepsis, septic shock and mortality among emergency department patients with suspected sepsis [39].

Moreover, Chang et al. described plasma NGAL as a reliable predictor of 28-day mortality in severe sepsis [6]. Research by Wu et al. has shown that serum NGAL and lactate may serve as independent risk factors for 28-day mortality in sepsis patients [49]. Lentini et al. found that elevated plasma NGAL levels in patients with sepsis and AKI is associated with severity of the systemic inflammatory response [24]. Although NGAL is a significant biomarker for AKI in sepsis, it has been reported to be elevated in sepsis independently of renal injury [52]. Sepsis contributes to more than 20% of AKI cases in intensive care unit (ICU) patients, with cases severe enough to require renal replacement therapy [24].

Kidney failure

One of the most extensively researched areas of NGAL utility is the diagnosis of renal disorders. Numerous studies have demonstrated the role of NGAL in early diagnosis in AKI, predicting of progression in chronic kidney disease (CKD), and assessment of graft function following kidney trans-

plantation. NGAL concentrations are elevated in various types of CKD. Its diagnostic value has been tested in differentiating between primary inflammatory and non-inflammatory etiologies of CKD. Furthermore, NGAL can replace serum ferritin in the assessment of iron status in CKD patients, even those requiring renal replacement therapy [7,14,18,30,38].

In the kidneys, NGAL is secreted by epithelial cells of the loop of Henle, as well as the proximal and distal tubules, and its level increases in proportion to the degree of renal tubular injury, whether ischemic, nephrotoxic, inflammatory or septic in nature [27,44,48].

Research by Mellor showed that NGAL levels rise in response to prolonged hypobaric hypoxia and this increase may occur without concomitant acute kidney injury [28]. The development of proteinuria or acute kidney injury may be associated with rapid ascent to high altitudes. According to a study by Xiaoshan, the hypoxic and hypobaric environment at high altitudes may cause podocyte damage, promoting proteinuria and it is considered to play significant role in the development and progression of CKD [15,51]. Aviators exposed to gravitational forces are at risk of multiple organ injury, including the kidneys. In a study by Noddeland, aviators examined without anti-gravitational suits demonstrated proteinuria and the presence of hyaline casts [33]. Chang et al. demonstrated that pilots, particularly flying fighter aircraft, are at risk of developing hypertension, which may accelerate glomerular damage, inflammation and lead to a reduced number of glomeruli, affecting kidney structure and function and contributing to CKD [6].

Commonly used markers of kidney function, such as serum creatinine and blood urea nitrogen, reflect changes in the glomerular filtration rate, which typically occur as a manifestation of distinct kidney damage [42]. Novel biomarkers can indicate structural kidney damage before renal function begins to deteriorate. NGAL can be detected in plasma within two hours of AKI, with peak concentration after six hours [35]. Elevated plasma NGAL levels are observed for five days before gradually declining [47]. Urinary NGAL is also elevated in AKI. Both plasma and urinary NGAL can be detected earlier, even 24 hours prior to an increase in creatinine levels [30]. Elevated serum NGAL levels result from neutrophil and monocyte activation during the inflammatory response and from decreased renal function, which leads to the accumulation of plasma NGAL [14].

Sepsis with Acute Kidney Injury (AKI)

Up to 70% of AKI cases may be related to sepsis, which is strongly linked to adverse outcomes. Sepsis-associated AKI (SA-AKI) is defined as the occurrence of AKI within seven days of the onset of sepsis, diagnosed according to the criteria of the Kidney Disease: Improving Global Outcome (KDIGO) and Sepsis 3 [10]. SA-AKI is categorized into early, occurring within the first 48 hour of sepsis, and late, occurring between 48 hour and seven days after the onset of sepsis. SA-AKI is associated with a poorer prognosis among patients with sepsis [20]. Moreover, critically ill patients with sepsis, electrolyte imbalances, nephrotoxic drugs and hemodynamic instability are at higher risk of persistent AKI [36,40].

In addition to urine output and serum creatinine levels, which are components of AKI definition, several serum and urinary diagnostic and prognostic biomarkers have also been developed. These include interleukins 6, 8 and 18, osteopro-

tegerin, galectin-3, presepsin, cystatin C, NGAL, proenkephalin A, Chemokine (C-C motif) ligand (CCL-14), tissue inhibitor of metalloproteinases 2 (TIMP-2) and liver fatty acid-binding protein (L-FABP) [51]. Compared to creatine, NGAL has greater predictive value for AKI in sepsis patients [49].

The use of biomarkers may help overcome the limitations of current diagnostic standards for AKI and sepsis [10]. Although the mechanisms of action of these markers are not yet fully understood, they appear to increase predictive accuracy in the diagnosis of sepsis and AKI, particularly when used in combination with other known markers. Further research is needed to establish reference ranges for NGAL concentrations under various conditions. Moreover, the use of NGAL to identify specific sites of kidney tissue damage as well as its potential role in targeted therapy represent a promising area of investigation. The diagnostic accuracy of NGAL in sepsis and AKI requires further research.

AUTHORS' DECLARATION:

Study Design: Agnieszka Podgórska, Grzegorz Kade, Janusz Hałka. **Data Collection:** Agnieszka Podgórska, Grzegorz Kade, Janusz Hałka. **Manuscript Preparation:** Agnieszka Podgórska, Grzegorz Kade, Janusz Hałka.

The authors declare that there is no conflict of interest.

REFERENCES

1. Adegbite BR, Edoa JR, Ndzebe Ndoumba WF, Dimessa Mbadanga LB, Mombo-Ngoma G, Jacob ST, i in. A comparison of different scores for diagnosis and mortality prediction of adults with sepsis in Low-and-Middle-Income Countries: a systematic review and meta-analysis. *eClinicalMedicine*. grudzień 2021; 42:101184.
2. Akgul B, Bauer B, Zigrino P, Storey A, Mauch C, Pfister H. Upregulation of lipocalin-2 in human papillomavirus-positive keratinocytes and cutaneous squamous cell carcinomas. *J Gen Virol*. 1 luty 2011; 92(2):395–401.
3. Angus DC, Van Der Poll T. Severe Sepsis and Septic Shock. *N Engl J Med*. 29 sierpień 2013; 369(9):840–51.
4. Beghini J, Giraldo PC, Eleutério J, Amaral RLD, Polpetta NC, Gonçalves AK. Vaginal Inflammation: Association between Leukocyte Concentration and Levels of Immune Mediators. *Am J Reprod Immunol*. luty 2016; 75(2):126–33.
5. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased Plasma Neutrophil Gelatinase-Associated Lipocalin Levels Predict Mortality in Elderly Patients with Chronic Heart Failure. *Rejuvenation Res*. luty 2009; 12(1):7–14.
6. Chang H-F, Tsai C-D, Jhang G-C, Lee M-H, Chiu Y-L, Wu W-C, i in. Prevalence and factors associated with chronic kidney disease among military aircrews. *J Med Sci*. 2015; 35(2):50.
7. Choi HM, Park KT, Lee JW, Cho E, Jo SK, Cho WY, i in. Urine Neutrophil Gelatinase-Associated Lipocalin Predicts Graft Outcome up to 1 Year After Kidney Transplantation. *Transplant Proc*. styczeń 2013; 45(1):122–8.
8. Du Z-P, Wu B-L, Xie Y-M, Zhang Y-L, Liao L-D, Zhou F, i in. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop. *Biochim Biophys Acta BBA - Mol Cell Res*. październik 2015; 1853(10):2240–50.
9. Fernández CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients. *Clin Cancer Res*. 1 sierpień 2005; 11(15):5390–5.

10. Ferreira GS, Frota ML, Gonzaga MJD, Vattimo M de FF, Lima C. The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury. *Biomedicines*. 23 kwiecień 2024; 12(5):931.
11. Ferreira MC, Whibley N, Mamo AJ, Siebenlist U, Chan YR, Gaffen SL. Interleukin-17-Induced Protein Lipocalin 2 Is Dispensable for Immunity to Oral Candidiasis. *Deepe GS, redaktor. Infect Immun*. marzec 2014; 82(3):1030–5.
12. Freitas IAD, Lima NDA, Silva Jr GBD, Castro Jr RLD, Patel P, Lima CCDV, i in. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. *Rev Port Cardiol*. listopad 2020; 39(11):667–72.
13. Gowri M, Iyadurai R, Abhilash KPP, Paul A, Newbigging NS, Lenin A, i in. Role of Neutrophil Gelatinase-associated Lipocalin (NGAL) and Other Clinical Parameters as Predictors of Bacterial Sepsis in Patients Presenting to the Emergency Department with Fever. *Indian J Crit Care Med*. 28 luty 2023; 27(3):176–82.
14. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. *J Am Soc Nephrol JASN*. marzec 2008; 19(3):547–58.
15. Hansen JM, Olsen NV, Feldt-Rasmussen B, Kanstrup IL, Dechaux M, Dubray C, i in. Albuminuria and overall capillary permeability of albumin in acute altitude hypoxia. *J Appl Physiol*. 1 maj 1994; 76(5):1922–7.
16. Hjortebjerg R, Lindberg S, Pedersen S, Mogelvang R, Jensen JS, Oxvig C, i in. Insulin-Like Growth Factor Binding Protein 4 Fragments Provide Incremental Prognostic Information on Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction. *J Am Heart Assoc*. marzec 2017; 6(3):e005358.
17. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, i in. The neutrophil gelatinase-associated lipocalin (NGAL), a NF- κ B-regulated gene, is a survival factor for thyroid neoplastic cells. *Proc Natl Acad Sci*. 16 wrzesień 2008; 105(37):14058–63.
18. Kim IY, Kim JH, Lee DW, Lee SB, Rhee H, Song SH, i in. Plasma neutrophil gelatinase-associated lipocalin is associated with iron status in anemic patients with pre-dialysis chronic kidney disease. *Clin Exp Nephrol*. luty 2018; 22(1):28–34.
19. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J Biol Chem*. 15 maj 1993; 268(14):10425–32.
20. Kounatidis D, Vallianou NG, Psallida S, Panagopoulos F, Margellou E, Tsilingiris D, i in. Sepsis-Associated Acute Kidney Injury: Where Are We Now? *Medicina (Mex)*. 6 marzec 2024; 60(3):434.
21. Kubben FJGM, Sier CFM, Hawinkels LJAC, Tschesche H, Van Duijn W, Zuidwijk K, i in. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. *Eur J Cancer*. sierpień 2007; 43(12):1869–76.
22. Latoch E, Konończuk K, Taranta-Janusz K, Muszyńska-Roslan K, Szymczak E, Wasilewska A, i in. Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors. *Cancer Chemother Pharmacol*. grudzień 2020; 86(6):741–9.
23. Laurberg M, Saegerman C, Jacobsen S, Berg LC, Laursen SH, Hoeberg E, i in. Use of admission serum neutrophil gelatinase-associated lipocalin (NGAL) concentrations as a marker of sepsis and outcome in neonatal foals. *Abuelo A, redaktor. PLOS ONE*. 18 maj 2023; 18(5):e0285819.
24. Lentini P, De Cal M, Clementi A, D'Angelo A, Ronco C. Sepsis and AKI in ICU Patients: The Role of Plasma Biomarkers. *Crit Care Res Pract*. 2012; 2012:1–5.
25. Liu Z, Petersen R, Devireddy L. Impaired neutrophil function in 24p3 null mice contributes to enhanced susceptibility to bacterial infections. *J Immunol Baltim Md 1950*. 1 maj 2013; 190(9):4692–706.
26. Macdonald SPJ, Bosio E, Neil C, Arendts G, Burrows S, Smart L, i in. Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis. *Inflamm Res*. lipiec 2017; 66(7):611–9.
27. Macdonald SPJ, Stone SF, Neil CL, van Eeden PE, Fatovich DM, Arendts G, i in. Sustained elevation of resistin, NGAL and IL-8 are associated with severe sepsis/septic shock in the emergency department. *PLoS One*. 2014; 9(10):e110678.
28. Mellor A, Boos C, Stacey M, Hooper T, Smith C, Begley J, i in. Neutrophil Gelatinase-Associated Lipocalin: Its Response to Hypoxia and Association with Acute Mountain Sickness. *Dis Markers*. 2013; 35:537–42.
29. Miharada K, Hiroyama T, Sudo K, Danjo I, Nagasawa T, Nakamura Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. *J Cell Physiol*. maj 2008; 215(2):526–37.
30. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, i in. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *The Lancet*. kwiecień 2005; 365(9466):1231–8.
31. Nasioudis D, Witkin SS. Neutrophil gelatinase-associated lipocalin and innate immune responses to bacterial infections. *Med Microbiol Immunol (Berl)*. sierpień 2015; 204(4):471–9.
32. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, i in. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. *Diabet Med*. październik 2010; 27(10):1144–50.
33. Noddeland H, Myhre K, Balldin UI, Andersen HT. Proteinuria in fighter pilots after high +Gz exposure. *Aviat Space Environ Med*. luty 1986; 57(2):122–5.

34. Ragán D, Horváth-Szalai Z, Szirmay B, Mühl D. Novel Damage Biomarkers of Sepsis-Related Acute Kidney Injury. *EJIFCC*. kwiecień 2022; 33(1):11–22.
35. Romejko K, Markowska M, Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). *Int J Mol Sci*. 21 czerwiec 2023; 24(13):10470.
36. Samoni S, De Rosa S, Ronco C, Castellano G. Update on persistent acute kidney injury in critical illnesses. *Clin Kidney J*. 31 październik 2023; 16(11):1813–23.
37. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, i in. Dual Action of Neutrophil Gelatinase-Associated Lipocalin. *J Am Soc Nephrol*. luty 2007; 18(2):407–13.
38. Seibert FS, Sitz M, Passfall J, Haesner M, Laschinski P, Buhl M, i in. Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases. *Ren Fail*. 1 styczeń 2021; 43(1):417–24.
39. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, i in. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis: *Crit Care Med*. styczeń 2009; 37(1):96–104.
40. Shi K, Jiang W, Song L, Li X, Zhang C, Li L, i in. Persistent acute kidney injury biomarkers: A systematic review and meta-analysis. *Clin Chim Acta*. styczeń 2025; 564:119907.
41. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, i in. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. *Cancer Chemother Pharmacol*. listopad 2015; 76(5):989–96.
42. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, i in. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. *Cancer Chemother Pharmacol*. listopad 2015; 76(5):989–96.
43. Sikora JP, Karawani J, Sobczak J. Neutrophils and the Systemic Inflammatory Response Syndrome (SIRS). *Int J Mol Sci*. 30 sierpień 2023; 24(17):13469.
44. Tung M, Hsieh S, Yang S, Cheng C, Tsai R, Wang S, i in. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. *The Prostate*. wrzesień 2013; 73(12):1281–90.
45. Vajrychova M, Kacerovsky M, Tambor V, Hornychova H, Lenco J. Microbial invasion and histological chorioamnionitis upregulate neutrophil-gelatinase associated lipocalin in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med*. 2 styczeń 2016; 29(1):12–21.
46. Wang H, Zhang M, Mao H, Cheng Z, Zhang Q, Jiang C, i in. Serum neutrophil gelatinase-associated lipocalin and proinflammatory cytokines in pigs with septic versus non-septic acute kidney injury. *Int Urol Nephrol*. luty 2015; 47(2):413–20.
47. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? *Clin Chim Acta*. styczeń 2015; 438:350–7.
48. Westhoff JH, Seibert FS, Waldherr S, Bauer F, Tönshoff B, Fichtner A, i in. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury. *Eur J Pediatr*. czerwiec 2017; 176(6):745–55.
49. Wu Y, Yu C, Zhou Y, He Z-M, Zhang W, Fan J, i in. Risk stratification and prognostic value of serum neutrophil gelatinase-associated lipocalin (sNGAL) in sepsis patients. *Acta Biochim Pol [Internet]*. 28 luty 2022 [cytowane 2 kwiecień 2025]; . Pobrano z: https://www.frontierspartnerships.org/articles/10.18388/abp.2020_5755/pdf
50. Xiao R, Chen R. Neutrophil gelatinase-associated lipocalin as a potential novel biomarker for ventilator-associated lung injury. *Mol Med Rep*. czerwiec 2017; 15(6):3535–40.
51. Xiaoshan Z, Huan C, Zhilin G, Liwen M, Yan Z, Yue C. Hypoxia-inducible factor-1 α attenuates renal podocyte injury in male rats in a simulated high-altitude environment by upregulating Krüppel-like factor 4 expression. *Exp Physiol*. lipiec 2024; 109(7):1188–98.
52. Zhang A, Cai Y, Wang P-F, Qu J-N, Luo Z-C, Chen X-D, i in. Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis. *Crit Care*. 16 luty 2016; 20(1):41.